BioAge Labs (NASDAQ:BIOA) Shares Up 7.1% – Time to Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) shares traded up 7.1% on Tuesday . The company traded as high as $18.90 and last traded at $19.11. 610,777 shares changed hands during trading, a decline of 41% from the average session volume of 1,033,453 shares. The stock had previously closed at $17.85.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Citigroup increased their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Price Performance

The company has a market cap of $741.74 million, a price-to-earnings ratio of -13.61 and a beta of 1.38. The stock has a 50-day moving average price of $11.11 and a 200 day moving average price of $7.22.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Insiders Place Their Bets

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of BioAge Labs stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

Several institutional investors and hedge funds have recently bought and sold shares of BIOA. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs during the 3rd quarter worth approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after buying an additional 5,976 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs in the second quarter valued at $57,000. Finally, Intech Investment Management LLC acquired a new position in BioAge Labs during the second quarter worth $60,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.